SG11202002968UA - Compound having erk kinase inhibitory activity and use thereof - Google Patents
Compound having erk kinase inhibitory activity and use thereofInfo
- Publication number
- SG11202002968UA SG11202002968UA SG11202002968UA SG11202002968UA SG11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA SG 11202002968U A SG11202002968U A SG 11202002968UA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- inhibitory activity
- kinase inhibitory
- erk kinase
- erk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710915493 | 2017-09-30 | ||
| PCT/CN2018/108762 WO2019062949A1 (fr) | 2017-09-30 | 2018-09-29 | Composé présentant une activité inhibitrice de kinase erk et son utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002968UA true SG11202002968UA (en) | 2020-04-29 |
Family
ID=65902341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002968UA SG11202002968UA (en) | 2017-09-30 | 2018-09-29 | Compound having erk kinase inhibitory activity and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11465984B2 (fr) |
| EP (1) | EP3702354B1 (fr) |
| JP (1) | JP7216105B2 (fr) |
| KR (1) | KR20200078510A (fr) |
| CN (1) | CN109863147A (fr) |
| AU (1) | AU2018339722B2 (fr) |
| BR (1) | BR112020006294A2 (fr) |
| CA (1) | CA3080623C (fr) |
| EA (1) | EA202090888A1 (fr) |
| IL (1) | IL273655B2 (fr) |
| MX (1) | MX2020003240A (fr) |
| NZ (1) | NZ763197A (fr) |
| SG (1) | SG11202002968UA (fr) |
| WO (1) | WO2019062949A1 (fr) |
| ZA (1) | ZA202001823B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023080193A1 (fr) * | 2021-11-04 | 2023-05-11 | 日産化学株式会社 | Procédé de production d'un composé d'indole |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106928216A (zh) * | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| CN108697710B (zh) * | 2016-01-22 | 2022-02-18 | 杨森制药有限公司 | 作为nik抑制剂的新颖的经取代的氰基吲哚啉衍生物 |
| EP3405464B1 (fr) * | 2016-01-22 | 2019-12-04 | Janssen Pharmaceutica NV | Nouveaux dérivés de pyridinone substituée 5- (2-amino-4-pyrimidinyle)-cyanoindoline en tant qu'inhibiteurs de nik |
-
2018
- 2018-09-29 AU AU2018339722A patent/AU2018339722B2/en active Active
- 2018-09-29 JP JP2020539131A patent/JP7216105B2/ja active Active
- 2018-09-29 NZ NZ763197A patent/NZ763197A/en unknown
- 2018-09-29 SG SG11202002968UA patent/SG11202002968UA/en unknown
- 2018-09-29 EA EA202090888A patent/EA202090888A1/ru unknown
- 2018-09-29 US US16/652,148 patent/US11465984B2/en active Active
- 2018-09-29 BR BR112020006294-4A patent/BR112020006294A2/pt unknown
- 2018-09-29 CN CN201880001907.6A patent/CN109863147A/zh active Pending
- 2018-09-29 KR KR1020207012147A patent/KR20200078510A/ko active IP Right Grant
- 2018-09-29 WO PCT/CN2018/108762 patent/WO2019062949A1/fr active Application Filing
- 2018-09-29 MX MX2020003240A patent/MX2020003240A/es unknown
- 2018-09-29 IL IL273655A patent/IL273655B2/en unknown
- 2018-09-29 EP EP18862819.2A patent/EP3702354B1/fr active Active
- 2018-09-29 CA CA3080623A patent/CA3080623C/fr active Active
-
2020
- 2020-03-23 ZA ZA2020/01823A patent/ZA202001823B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202001823B (en) | 2022-10-26 |
| JP7216105B2 (ja) | 2023-01-31 |
| MX2020003240A (es) | 2020-11-24 |
| CA3080623A1 (fr) | 2019-04-04 |
| AU2018339722A1 (en) | 2020-04-23 |
| AU2018339722B2 (en) | 2022-06-30 |
| US20200247781A1 (en) | 2020-08-06 |
| KR20200078510A (ko) | 2020-07-01 |
| EP3702354A1 (fr) | 2020-09-02 |
| CN109863147A (zh) | 2019-06-07 |
| JP2020536120A (ja) | 2020-12-10 |
| US11465984B2 (en) | 2022-10-11 |
| BR112020006294A2 (pt) | 2020-10-06 |
| EP3702354A4 (fr) | 2021-02-24 |
| WO2019062949A1 (fr) | 2019-04-04 |
| EP3702354B1 (fr) | 2024-05-22 |
| NZ763197A (en) | 2024-03-22 |
| EA202090888A1 (ru) | 2021-01-27 |
| IL273655B1 (en) | 2023-05-01 |
| IL273655A (en) | 2020-05-31 |
| IL273655B2 (en) | 2023-09-01 |
| CA3080623C (fr) | 2023-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001340B (en) | Heterocyclic compound and use thereof | |
| EP3486244A4 (fr) | Nouveau composé présentant une activité inhibitrice du fgfr, préparation et application correspondantes | |
| EP3620456A4 (fr) | Composé présentant une activité inhibitrice de kinase, son procédé de préparation et son utilisation | |
| EP3337375A4 (fr) | Panier et lave-vaisselle le comprenant | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| EP3337376A4 (fr) | Panier et lave-vaisselle le comprenant | |
| EP3555051A4 (fr) | Inhibiteurs d'héparanase et leur utilisation | |
| IL279276A (en) | ERK inhibitor and use thereof | |
| KR102135648B9 (ko) | 항독성 또는 항병원성 활성을 갖는 레오이딘 화합물 및 이의 용도 | |
| EP3564242A4 (fr) | Composé pour inhiber sélectivement la kinase et son utilisation | |
| EP3409668A4 (fr) | Nouveau dérivé d'imidazole présentant une activité inhibitrice de la jnk et son utilisation | |
| IL273655B1 (en) | A compound with erk kinase inhibitory activity and its use | |
| EP3246312A4 (fr) | Composé carbamate et son utilisation | |
| EP3246319A4 (fr) | Composé de carbamate et son utilisation | |
| EP3246314A4 (fr) | Composé carbamate et utilisation associée | |
| IL258370A (en) | Oxa-diazaspiro compounds with analgesic activity | |
| IL283106A (en) | erk inhibitors and their uses | |
| EP3305895A4 (fr) | Variant de bêta-galactosidase présentant une forte activité de transglycosylation et utilisation de ce dernier | |
| EP3246316A4 (fr) | Composé carbamate et utilisation associée | |
| EP3246318A4 (fr) | Composé de type carbamate et son utilisation | |
| HK1255248A1 (zh) | 對疼痛具有多模式活性的酰胺衍生物 | |
| EP3607339A4 (fr) | Irm d'activité | |
| EP3555071A4 (fr) | Inhibiteurs d'héparanase et leur utilisation | |
| IL284285A (en) | Domperidone combinations against neurodegeneration and use |